EICHOR
● Terminated
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
Condition: Metastatic NSCLC · Sponsor: BrightPath Biotherapeutics
About this study
This is a non-randomized, Phase 2, 2-stage, open-label, multi-center study of GRN-1201/sargramostim + pembrolizumab in subjects with PD-L1+ metastatic NSCLC. All subjects will have newly diagnosed metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Subjects with EGFR or ALK genomic tumor aberrations with progression on FDA-approved therapy for these aberrations are eligible
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (11)
| St Joseph Hospital of Orange | Orange, California, United States | — |
| University of Colorado Cancer Center | Aurora, Colorado, United States | — |
| Florida Hosptial Cancer Center- AdventHealth | Orlando, Florida, United States | — |
| Robert H Lurie Cancer Center at Northwestern University | Chicago, Illinois, United States | — |
| University of Illinois at Chicago | Chicago, Illinois, United States | — |
| Orchard Healthcare | Skokie, Illinois, United States | — |
| Norton Healthcare Cancer Institute | Louisville, Kentucky, United States | — |
| East Jefferson General Hospital | Metairie, Louisiana, United States | — |
| Ocshner Cancer Institute | New Orleans, Louisiana, United States | — |
| Dartmouth Hitchcock Medical Center | Lebanon, New Hampshire, United States | — |
| Virginia Cancer Institute | Richmond, Virginia, United States | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03417882